AB Private Credit Investors Q3 2026 10-Q: NAV $9.18, Tender at 72% of Cap, 8 Non-Accruals
Some links pay us a referral fee; each one says so. Disclosure
Filing alert · free
An email when AB Private Credit Investors Corporation (ABPCI) files with the SEC
An email the day AB Private Credit Investors Corporation (ABPCI) files something new, with the link to the document on the SEC site.
Quick answer
AB Private Credit Investors Corporation (ABPCI, CIK 1634452), a private non-traded BDC, reported in its Form 10-Q filed November 13, 2026 (accession 0001193125-26-460862) a NAV of $9.18 a share at September 30, 2026, up from $9.15 at June 30, 2026 and down from $9.47 at December 31, 2025 (as of November 16, 2026). Net assets were $748,743,789 on 81,571,157 shares. Third-quarter net investment income of $16,693,502 matched the $16,690,480 distribution declared ($0.21 a share each). In the offer that expired September 30, 2026, holders tendered 1,416,294.288 shares, 71.8% of the 1,971,887-share cap and the largest share of any of the 12 results we read since December 2023; the fund bought all of them at $9.18 for $13,000,165.27. Eight issuers were on non-accrual, $43,172,162 at cost and $14,106,165 at fair value (0.72% of debt), down from nine issuers and $24,497,366 at June 30, 2026. Borrowings under the credit lines rose to $786,750,000 and asset coverage fell to 157% against a 150% minimum.
Key takeaways
- NAV turned up by three cents in the quarter, $9.15 to $9.18 (+0.3%), but is still $0.29, or 3.1%, below the $9.47 of December 31, 2025 (our arithmetic). Net realized and unrealized results were a loss of $0.30 a share over nine months against income of $0.61 and distributions of $0.60. Total return at NAV after incentive fees was 3.32% for the nine months, not annualized.
- The payout is earned, to the dollar. Third-quarter net investment income was $16,693,502 against $16,690,480 of distributions declared, 100.0% (our arithmetic), and nine-month income of $47,862,325 against $47,860,413. The September 28, 2026 distribution of $0.21 was up from $0.19 in June 2026. Interest and borrowing expenses took 40.3% of third-quarter investment income (our arithmetic).
- Tender requests hit a high. The September 30, 2026 offer drew 1,416,294.288 shares, 71.8% of the cap and 57.5% more than the 899,104.822 of June 2026 (our arithmetic); the previous high was 71.5% in June 2024. Everything was bought, and it left 555,592.712 shares of room under the cap (our arithmetic). No offer for December 31, 2026 had been filed as of November 16, 2026.
- Non-accruals fell, but from a high base and with six of eight loans maturing by December 31, 2026. Fair value on non-accrual dropped $10,391,201 in the quarter (our arithmetic) because MedMark Services, Inc., carried at $6,744,898 on June 30, is no longer on the list. One issuer, RCP Encore Acquisition, Inc., is carried at $28,285 on $2,828,499 of principal.
- New money is shrinking while requests grow. Capital drawdowns were $8,736,139 in the third quarter against $44,862,506 a year earlier, and over nine months drawdowns plus reinvested distributions less repurchases added $42,089,579 of equity against $91,427,250 in 2025 (our arithmetic). The 10-Q also shows $12,385,866 of capital commitments released in the quarter because holders tendered.
- Leverage rose to 1.77 times net assets. Credit lines drawn went from $716,250,000 to $786,750,000 and CLO notes are $538,000,000, so senior securities were $1,324,750,000 and asset coverage 157% (our arithmetic, 10-Q). On October 15, 2026 a new $195 million KeyBank loan repaid the $151,250,000 MUFG line; the first 8-K did not say so and an amendment added it.
- Two maturities that fell in the weeks after the quarter-end are resolved or empty: the Scotia line, $150,000,000 drawn, was extended from November 6, 2026 to November 8, 2027 on November 6, 2026, and the HSBC line had nothing drawn at September 30, 2026 ahead of its December 7, 2026 maturity.
CSV · 243 rows
AB Private Credit Investors Corporation (ABPCI) Q3 2026 10-Q: NAV, income against distributions, non-accruals by issuer, debt, tender results and capital calls
243 rows from the Forms 10-Q for September 30 and June 30, 2026, 12 Schedule TO-I/A results from February 2024 to November 12, 2026, the Schedule TO-I of August 28, 2026 and the Forms 8-K and 8-K/A of September 22, October 15 to 29, October 22 and November 6, 2026: NAV, income against distributions, non-accruals by issuer, debt by lender, tender results and capital calls. Form and accession number on every row.
What changed between June 30 and September 30, 2026
Our page on the fund, AB Private Credit Investors Corporation: NAV, debt and tenders, covers the June 30, 2026 balance sheet, the eleven tender results to that date and the vote on the new advisory agreement. The 10-Q filed November 13, 2026 is the first look at the September 30 statements, and it moves the credit, tender and financing numbers in different directions.
| Measure | Dec 31, 2025 | Jun 30, 2026 | Sep 30, 2026 | Change in the quarter (our arithmetic) |
|---|---|---|---|---|
| NAV per share | $9.47 | $9.15 | $9.18 | +$0.03 (+0.3%) |
| Total net assets | $730,348,731 | $741,611,119 | $748,743,789 | +$7,132,670 (+1.0%) |
| Shares outstanding | 77,076,615 | 81,022,158 | 81,571,157 | +548,999 |
| Portfolio companies | 161 | 165 | 170 | +5 |
| Issuers on non-accrual | 6 | 9 | 8 | -1 |
| Non-accrual debt at amortized cost | $29,405,603 | $53,635,416 | $43,172,162 | -$10,463,254 |
| Non-accrual debt at fair value | $9,055,033 | $24,497,366 | $14,106,165 | -$10,391,201 |
| Credit facilities drawn | $680,000,000 | $716,250,000 | $786,750,000 | +$70,500,000 |
| Senior securities (lines plus CLO notes) | $1,218,000,000 | $1,254,250,000 | $1,324,750,000 | +$70,500,000 |
| Asset coverage ratio | 160% | 159% | 157% | -2 points |
| Cash and cash equivalents | $105,808,043 | $81,300,624 | $79,255,994 | -$2,044,630 |
| Shares tendered in that quarter's offer | 539,142.494 | 899,104.822 | 1,416,294.288 | +517,189.466 (+57.5%) |
The September 30, 2026 senior securities figure is the sum of $786,750,000 on the credit lines and the $538,000,000 of CLO notes the 10-Q lists (our arithmetic); the June 30 figure is the one the June 10-Q reports. The September ratio is the 10-Q's own. The tender row shows the shares tendered in the offer that expired in the quarter shown (the December 31, 2025 offer for the first column).
NAV and the payout: earned, with nothing to spare
The nine-month financial highlights give the whole bridge from $9.47 to $9.18 in per-share terms: net investment income of $0.61, a net realized and unrealized loss of $0.30 and distributions of $0.60. The quarter was quiet by comparison: income of $0.21 a share, a net realized and unrealized gain of $2,089,575 ($0.03 a share, our arithmetic) and a distribution of $0.21.
| Period | Net investment income | Distributions declared | Income as % of distributions (our arithmetic) | Net increase in net assets from operations |
|---|---|---|---|---|
| Third quarter 2026 | $16,693,502 ($0.21 a share) | $16,690,480 ($0.21 a share) | 100.0% | $18,783,077 |
| Nine months 2026 | $47,862,325 ($0.61 a share) | $47,860,413 ($0.60 a share) | 100.0% | $24,160,442 |
| Nine months 2025 | $42,251,117 ($0.62 a share) | $42,247,481 ($0.60 a share) | 100.0% | $41,739,731 |
The 2026 distributions declared were $0.20 on March 27, $0.19 on June 26 and $0.21 on September 28, 2026, payable April 23, July 22 and October 22, 2026. The fund covers its payout, as it did in 2025, but it does so with leverage and fees underneath: interest and borrowing expenses were $19,167,953 in the quarter, 40.3% of total investment income of $47,559,474 (our arithmetic), and the nine-month ratio of total expenses to weighted average net assets was 15.86%, annualized. Interest and credit facility expenses alone were 10.13% of net assets, down from 12.16% a year earlier, because the weighted average interest rate on borrowings fell from 6.73% to 5.60% in the third quarter. The adviser waived $271,957 of management fees and $245,475 of incentive fees in the nine months and none in the third quarter.
Reinvestment keeps the share count rising. In the third quarter, 1,013,541 shares worth $9,303,290 were issued under the dividend reinvestment plan, 55.7% of the distribution declared that quarter (our arithmetic: $9,303,290 of $16,690,480 for the September 28 record date). The share count grew by 548,999 even as the fund bought back 1,416,294.
Tender offers: the largest request in 12 results
Each row is the result the fund filed in the Schedule TO-I/A that closes the offer. The cap is 2.5% of the weighted average shares outstanding in the prior quarter; for the September 30, 2026 offer that was 78,875,500 shares (Schedule TO-I of August 28, 2026). The filings give shares validly tendered and accepted, so a request above the cap would show as proration, which has not happened.
| Offer expired | Cap (shares) | Shares tendered | Tendered as % of cap | Accepted | Price per share | Cash paid |
|---|---|---|---|---|---|---|
| Dec 29, 2023 | 1,320,791.88 | 531,602.422 | 40.2% | 100% | $9.2743 | $4,930,240.32 |
| Mar 29, 2024 | 1,354,873.30 | 744,282.453 | 54.9% | 100% | $9.398 | $6,994,766.47 |
| Jun 28, 2024 | 1,379,302.80 | 985,757.156 | 71.5% | 100% | $9.4505 | $9,315,898.00 |
| Sep 30, 2024 | 1,430,285.6 | 737,478.531 | 51.6% | 100% | $9.4531 | $6,971,458.29 |
| Dec 31, 2024 | 1,515,531.175 | 822,521.923 | 54.3% | 100% | $9.53 | $7,838,222.68 |
| Mar 31, 2025 | 1,594,397.375 | 767,533.732 | 48.1% | 100% | $9.54 | $7,320,890.25 |
| Jun 30, 2025 | 1,663,967.65 | 854,554.254 | 51.4% | 100% | $9.49 | $8,108,694.41 |
| Sep 30, 2025 | 1,713,208.35 | 768,406.926 | 44.9% | 100% | $9.53 | $7,321,765.38 |
| Dec 31, 2025 | 1,749,969.45 | 539,142.494 | 30.8% | 100% | $9.48 | $5,108,698.60 |
| Mar 31, 2026 | 1,861,300.28 | 1,188,529.778 | 63.9% | 100% | $9.21 | $10,946,359.25 |
| Jun 30, 2026 | 1,935,427.95 | 899,104.822 | 46.5% | 100% | $9.15 | $8,229,686.23 |
| Sep 30, 2026 | 1,971,887 | 1,416,294.288 | 71.8% | 100% | $9.18 | $13,000,165.27 |
Percent of cap is our arithmetic. Over the 12 results the fund bought 10,255,208.779 shares for $96,086,845.15 (our sums). The March 31, 2026 price is the $9.21 in the 10-Q's repurchase table and in the cash paid divided by shares tendered; the May 12, 2026 amendment shows $9.48.
What is new. Only three of the 12 results passed 60% of the cap: 71.5% in June 2024, 63.9% in March 2026 and now 71.8%. The jump from June is 517,189.466 shares, or 57.5% (our arithmetic). The fund paid on November 5, 2026, 36 days after expiry, by promissory note (Schedule TO-I/A). The cap left 555,592.712 shares unused, 28.2% of it (our arithmetic).
The link between tendering and new money. The 10-Q reports “Capital Commitments rescinded due to participation in General Tender Program”: $12,385,866 in the third quarter against $8,583,000 a year earlier, and $34,121,669 for nine months against $24,650,224. A holder who tenders can have the unfunded part of the commitment released, so a tender does not only take cash out; it shrinks the fund's future capital calls. Total commitments were $802,024,772 at September 30, 2026, 19% or $151,987,120 unfunded, from $775,624,993 at December 31, 2025.
The next offer. The fund filed its fourth-quarter Schedule TO-I on November 29, 2024 and November 28, 2025, with a cap of 2.5% of the weighted average shares of the third quarter each time, and there is nothing on EDGAR for the quarter ending December 31, 2026 as of November 16, 2026. If the same 2.5% applied to the third-quarter weighted average of 81,027,856 shares, the cap would be about 2,025,696 shares, 1.43 times the September request (our arithmetic). Requests would have to rise 43% to reach it. The price would be the NAV at December 31, 2026, which no one knows when tendering. The 10-Q says: “The General Tender Program includes numerous restrictions that limit stockholders’ ability to sell their Shares.”
The record goes back further than the twelve results above. The fund has run a quarterly general tender offer since the quarter ended March 31, 2021: 23 offers through the one that expired September 30, 2026, and the result filing for each one says all tendered shares were accepted (Schedule TO-I/A filings, first result acc. 0001193125-21-156048, latest acc. 0001193125-26-458089). The 11 earlier results run from April 2021 to September 2023. In the first offer the cap was raised from 502,190.45 to 2,083,220 shares and holders tendered 1,173,288.456 (Schedule TO-I/A acc. 0001193125-21-101836 and 0001193125-21-156048); in the offer that expired September 30, 2021 the fund bought 887,496.525 shares against a cap of 684,540.65 (acc. 0001193125-21-325544).
Credit: eight issuers on non-accrual, six with loans due by December 31, 2026
At September 30, 2026, 26 investments in eight issuers were on non-accrual, against 32 in nine issuers at June 30 and 19 in six at December 31, 2025. Debt on non-accrual was 2.14% of debt at cost and 0.72% at fair value, against 2.77% and 1.30% at June 30 and 1.61% and 0.50% at December 31, 2025. The per-issuer figures below are our sums of the schedule-of-investments rows the 10-Q marks as non-accrual; the eight sums equal the reported $43,172,162 at cost and $14,106,165 at fair value.
| Issuer | Industry | Cost, Sep 30, 2026 | Fair value, Sep 30, 2026 | Fair value, Jun 30, 2026 | Loan maturities shown |
|---|---|---|---|---|---|
| American Physician Partners, LLC | Health care providers and services | $11,499,973 | $0 | $0 | Dec 31, 2026 |
| Blink Holdings, Inc. | Hotels, restaurants and leisure | $1,575,652 | $0 | $0 | Dec 31, 2026 |
| Delaware Valley Management Holdings, Inc. | Health care providers and services | $2,030,867 | $782,930 | $783,143 | Dec 31, 2026 |
| MSM Acquisitions, Inc. | Media | $12,976,224 | $8,007,725 | $9,020,948 | Dec 9, 2026 |
| RCP Encore Acquisition, Inc. | Health care providers and services | $2,761,172 | $28,285 | $28,305 | Dec 31, 2026 |
| Sandstone Care Holdings, LLC | Health care providers and services | $4,618,244 | $3,245,225 | $5,346,030 | Jun 28, 2028 |
| SCA Buyer, LLC | Pharmaceuticals | $4,581,455 | $1,282,129 | $1,952,329 | Jan 20, 2027 |
| Single Digits, Inc. | Technology hardware, storage and peripherals | $3,128,575 | $759,871 | $621,713 | Dec 31, 2026 |
| Total | $43,172,162 | $14,106,165 | $17,752,468 |
The June 30 total in the table, $17,752,468, is the eight issuers still listed; the ninth, MedMark Services, Inc., was carried at $6,744,898 in the June 10-Q and has no non-accrual row in the September 30 schedule (our reading), which accounts for $6.74 million of the $10.39 million fall in fair value. The rest comes from Sandstone Care Holdings ($2.10 million lower), MSM Acquisitions ($1.01 million) and SCA Buyer ($0.67 million), partly offset by Single Digits ($0.14 million higher) (our arithmetic). The 10-Q does not say why MedMark left the list, and the third-quarter net realized loss was $1,646,528, so we do not link the two.
Four of the eight are health-care providers, as five of nine were in June. Six have loans maturing by December 31, 2026 (American Physician Partners, Blink, Delaware Valley, MSM, RCP Encore and Single Digits). A maturity on a non-accrual loan is a date for a decision, not a repayment: at June 30 the loans of American Physician Partners were shown due December 31, 2026, and they still are. The 10-Q's valuation table shows how the lowest marks are set: RCP Encore at 1.0% of principal (our arithmetic: $28,285 of $2,828,499) on a recent-transaction price and Delaware Valley at liquidation value ($782,930).
Across the whole debt book, non-accrual loans are small against $1,962,670,417 of debt at fair value, and the debt is 100% floating-rate across 170 portfolio companies. The quality of the other 99.28% is what the 10-Q's yield and marks cannot show: first-lien debt was 93.15% of the portfolio at fair value including cash, at a weighted average yield of 9.50% against 9.58% at December 31, 2025.
Debt: where the October 15 loan went
The 10-Q lists the credit lines at September 30, 2026, a quarter-end before the KeyBank loan.
| Credit line | Dec 31, 2025 drawn | Sep 30, 2026 committed | Sep 30, 2026 drawn | What happened after the quarter-end |
|---|---|---|---|---|
| HSBC | $0 | $42,000,000 | $0 | Matures Dec 7, 2026; nothing drawn |
| Synovus | $190,000,000 | $150,000,000 | $150,000,000 | Unchanged |
| Natixis | $235,000,000 | $325,000,000 | $266,000,000 | Unchanged |
| MUFG | $150,000,000 | $151,250,000 | $151,250,000 | Repaid and terminated Oct 15, 2026 |
| NatWest | $75,000,000 | $75,000,000 | $69,500,000 | Unchanged |
| Scotia | $30,000,000 | $150,000,000 | $150,000,000 | Maturity moved from Nov 6, 2026 to Nov 8, 2027 on Nov 6, 2026 |
| Total | $680,000,000 | $893,250,000 | $786,750,000 | $106,500,000 was available at Sep 30, 2026 |
KeyBank and MUFG. The Form 8-K filed October 21, 2026 reported a $195,000,000 Class A-T term loan to ABPCI Private Funding V LLC, up to $30,000,000 of delayed-draw loans until February 12, 2027, at three-month SOFR plus 1.74%, maturing September 30, 2035, and up to $105,900,000 of subordinated notes to the fund's depositor subsidiary. It did not say what the money was for. Form 8-K/A of October 29, 2026 adds that “Such disclosure was inadvertently omitted from the Original Filing”: the loan proceeds repaid the MUFG warehouse facility, up to $150,000,000 with a September 19, 2029 maturity, which was terminated. The 10-Q says the same in its subsequent events note. MUFG had $151,250,000 outstanding at September 30, 2026, so the new loan is $43,750,000 larger than the line it replaced (our arithmetic), before the delayed-draw part.
What it does to the ratio. The fund's asset coverage of 157% at September 30 compares with a 150% minimum. As an illustration only (our arithmetic): if the full $195,000,000 were outstanding, MUFG were gone and nothing else changed from September 30, senior securities would be $1,368,500,000 and asset coverage 154.7%, which leaves room for about $128.8 million more debt before 150%, against $172.6 million at September 30. The October 15 loan does not change that picture much; the quarter's $70.5 million of added borrowing did.
Scotia. The Form 8-K of November 10, 2026 reports the Third Amendment of November 6, 2026: maturity from November 6, 2026 to November 8, 2027 and a reset of the minimum shareholders' equity test. The 8-K does not give the new test. By drawn amount Natixis is the largest line at $266,000,000; Scotia and Synovus follow at $150,000,000 each.
Money in, money out
New equity comes through capital calls, announced in a Form 8-K (Item 3.02) days before the sale closes, and through dividend reinvestment.
| Item | Third quarter 2026 | Third quarter 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Capital drawdowns (value) | $8,736,139 | $44,862,506 | $47,729,744 | $90,937,340 |
| Dividend reinvestment | $9,303,290 | $8,062,281 | $26,536,044 | $23,241,222 |
| Shares purchased in tender offers | $13,000,165 | $7,321,727 | $32,176,209 | $22,751,312 |
| Net new equity (our arithmetic) | $5,039,264 | $45,603,060 | $42,089,579 | $91,427,250 |
| Capital commitments released by tendering | $12,385,866 | $8,583,000 | $34,121,669 | $24,650,224 |
The third-quarter call was $8,739,874.42 (Form 8-K, September 22, 2026, expected to close on or around October 1, 2026). A larger call followed on October 22, 2026: $16,690,524.39, expected to close on or around November 2, 2026. The notice does not say what it funds. It is dated the day the $16,690,480 distribution declared on September 28, 2026 was payable, and the two amounts differ by $44.39 (our arithmetic); the filing does not link them. After that call, about $135.3 million of commitments would remain uncalled if it closes in full (our arithmetic: $151,987,120 less $16,690,524.39), and the shares outstanding were 81,570,736.085 on November 1, 2026 (10-Q cover).
The fund invested $124,879,803 in 18 portfolio companies in the third quarter, drew $29,644,967 on revolvers and delayed-draw loans, and received $77,063,841 of principal repayments; unfunded commitments to portfolio companies were $327,558,737, up from $318,602,991 at June 30, 2026.
The vote of September 15, 2026 approved a new advisory agreement, needed because Equitable and Corebridge agreed to merge on March 26, 2026; 43,097,575 of 80,978,835.78 shares were represented (Form 8-K acc. 0001193125-26-391642; proxy acc. 0001193125-26-279743).
What to watch, with dates
- December 7, 2026: the HSBC line matures, with nothing drawn at September 30, 2026 (10-Q).
- December 9 and December 31, 2026: the maturities shown on loans of MSM Acquisitions (December 9, 2026) and five other non-accrual issuers (December 31, 2026). The next 10-Q will show which were extended, restructured or removed.
- Around late November 2026: the likely filing of the fourth-quarter Schedule TO-I, on the pattern of November 29, 2024 and November 28, 2025; the fund has announced nothing. The offer would price at the NAV on December 31, 2026.
- February 12, 2027: the last day the $30,000,000 of KeyBank delayed-draw loans can be borrowed (Form 8-K).
What a reader can do with this
If you hold the shares and want to sell. The September 30, 2026 offer filled every request at NAV, but it did so with the biggest request in the 12 results and a cap that was not reached by 28.2%. Tendering does not fix the price: the offer pays the NAV per share on the expiration date, which no one knows when the notice is sent. The sale is taxable; our page on wash sale rules for REIT, BDC and interval fund tenders covers the loss case, and how tender-offer funds work explains the filings.
If you hold and are staying. The numbers to follow are the NAV at December 31, 2026, whether the quarter's $0.21 distribution is still matched by income, the non-accrual list as its December maturities arrive, and the asset coverage ratio against 150%. Our non-traded BDC list puts the fund next to 66 others, the tender offer results page compares its September offer with other funds', and the BDC non-accrual census shows how its 0.72% looks across the group.
Ask the fund or your adviser three questions: what happened to MedMark Services, Inc., and at what price; what the new minimum shareholders' equity test is in the Scotia amendment; and how the fund would handle requests above the cap if the next offer drew more than the 71.8% of the September 30, 2026 offer.
This is analysis of public documents, not investment, legal or tax advice. If a meaningful part of your savings sits in one private credit fund, a conversation with a qualified adviser about your next tender decision and how the holding fits the rest of your portfolio may be worth having.
FAQ
All figures are from the SEC filings of AB Private Credit Investors Corporation (CIK 1634452) read on EDGAR on November 16, 2026: the Form 10-Q for September 30, 2026 (accession 0001193125-26-460862, filed November 13, 2026) and the Form 10-Q for June 30, 2026 (0001193125-26-352137); the final Schedule TO-I/A of November 12, 2026 (0001193125-26-458089) and the eleven earlier result filings from February 2024 to August 12, 2026; the Schedule TO-I of August 28, 2026 (0001193125-26-373361); the Forms 8-K of September 22, October 21 (0001193125-26-427754), October 22 and November 10, 2026 (0001193125-26-455671) and the Form 8-K/A of October 29, 2026 (0001193125-26-437510). The last filing on the CIK was the 10-Q of November 13, 2026. Percentages of the cap, changes between dates, sums across periods and offers, per-issuer non-accrual values and the asset coverage illustration are our arithmetic. This is analysis of public documents, not investment, legal or tax advice.